Charlottesville, VA – According to filings with the U.S. Securities and Exchange Commission, Gene Solutions is raising $2,300,000.00 in new funding. Sources indicate as part of senior management Cheif Financial Officer, Edward Connell played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gene Solutions

Gene Solutions conducts therapeutic drug discovery research for Central Nervous System (CNS) diseases, utilizing its proprietary mitochondrial genomic targets. The company’s primary CNS indications of interest are Alzheimer’s, Parkinson’s and Schizophrenia. NCE discovery research is conducted at the company’s two locations in the USA and UK, while company-developed assays are executed with leading academic collaboration partners. Adding to a comprehensive and unparalleled approach, the company’s unique biomarkers have utility in clinical patient screening and data generation, as well as blood-based companion diagnostics. We partner with pharmaceutical and biotechnology companies to bring novel and vital cures to large segments of our population.

To learn more about Gene Solutions, visit http://www.mitodna.com/

Contact:
Edward Connell, Cheif Financial Officer
434-326-7086

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved